Tuesday, January 17, 2017 8:25:38 AM
The expanding use of orals into first-line position is putting pressure on nearly all of the platform injectables, but most notably on Teva's Copaxone, for which surveyed neurologists have reported consecutive quarterly declines throughout 2016. Copaxone also faces a challenge from the first generic DMT to hit the market, Sandoz's Glatopa. The user base for Glatopa has been slowly expanding, driven largely by managed care mandates and although some neurologists (and their patients) are still reluctant to use Glatopa over Copaxone, willingness is higher to use Glatopa in the DMT-naïve patient as opposed to switching from Copaxone or other agents.
http://finance.yahoo.com/news/two-independent-studies-multiple-sclerosis-100000324.html
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM